NRG Therapeutics begins first-in-human trial for MND treatment.
The trial of NRG5051 aims to restore energy in nerve cells and slow disease progression.
Latest NRG Therapeutics News & Updates
See the latest news and media coverage for NRG Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage neuroscience company developing mitochondrial-targeted therapies for neurodegenerative diseases
nrgtherapeutics.com- Headquarters
- Stevenage, United Kingdom
- Company type
- Private company
- Number of employees
- 20–50
Last updated
Latest news about NRG Therapeutics
In short: NRG Therapeutics initiated its first-in-human clinical trial for NRG5051 and secured significant funding for neurodegenerative disease research.
Company announcements
NRG Therapeutics advances NRG5051 in clinical trials
They thank Stevenage Bioscience Catalyst for a video sharing their story. The company focuses on treatments for ALS, MND, and Parkinson's.
NRG Therapeutics celebrates featured 2025 £50m Series B
The funding tops UK life sciences deals in BIA report. Investors support NRG5051 for ALS, MND, and Parkinson's.
NRG Therapeutics executives attend JPMorgan Healthcare conference
They meet investors, pharma, and collaborators. NRG5051 enters first-in-human trials.
Media coverage
NRG raises £50m to start trials of Parkinson's, ALS drug
Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. NRG Therapeutics...
NRG announces £16m Series A for IND for Parkinson's and ALS
A £16 million Series A financing - led by Omega Funds - has been announced by the innovative neuroscience company NRG Therapeutics Ltd., for the...
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...
STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial...
NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
STEVENAGE, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG"), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction...
Never miss news about NRG Therapeutics
Track NRG Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
NRG Therapeutics competitors & trending companies
Browse news for competitors to NRG Therapeutics and other trending companies.
Clene
BioArctic
Abarceo Pharma
Raya
Acelot
Mitochon
Domyn
Mitsubishi Chemical Group
Teijin
Definium Therapeutics
SUNation
WIN Waste
Avient
Huntsman
Hexcel
Toray
Gurit
SGL Carbon
Ahlstrom
Park.Aero
Pantalones
Sakana AI
PartRunner
Power Integrations
Kroma
SocialLadder
CAMP
Wave
CardMedic
Bevz
InnerPlant
AgVend
Futuremood
Melboss
Geo-Solutions